Results 61 to 70 of about 20,750 (203)

Brain Metastases From Differentiated Thyroid Cancer in the Era of Targeted Therapies: A Multi‐Center Retrospective Cohort

Head &Neck, EarlyView.
ABSTRACT Background Brain metastases (BM) of differentiated thyroid carcinoma (DTC) are associated with unfavorable prognosis. This study evaluated BM management strategies and patients' outcomes. Methods A retrospective review of patients diagnosed with DTC and BM at Tel Aviv Sourasky and Rabin Medical Centers between 1985 and 2024. Clinical features,
Liyona Kampel, Shaun Edalati, Eyal Yosefof, Anton Warshavsky, Gilad Horowitz, Nidal Muhanna, Hagit Shoffel‐Havakuk, Eyal Robenshtok, Aron Popovtzer, Inbar Finkel   +9 more
wiley   +1 more source

Endoplasmic reticulum stress-induced autophagy determines the susceptibility of melanoma cells to dabrafenib

Drug Design, Development and Therapy, 2016
Chao Ji,1,2 Ziping Zhang,1,2 Lihong Chen,1,2 Kunli Zhou,1,2 Dongjun Li,1,2 Ping Wang,1,2 Shuying Huang,1,2 Ting Gong,2 Bo Cheng1,2 1Department of Dermatology, the 1st Affiliated Hospital of Fujian Medical University, 2Fujian Institute of ...
Ji C, Zhang ZP, Chen LH, Zhou KL, Li DJ, Wang P, Huang SY, Gong T, Cheng B   +8 more
doaj  

A Case of Pulmonary Sarcoidosis during First-Line Targeted Therapy with Dabrafenib Plus Trametinib in BRAF V600E-Mutated Metastatic Melanoma

Case Reports in Oncology, 2022
BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) exert a cytotoxic and immune-mediated effect on metastatic melanoma. The immune-mediated mechanism can lead to some adverse events, including panniculitis, erythema, keratitis, vitiligo-like lesions, or ...
Maria Chiara Tronconi, Arianna Marinello, Alessandra Solferino, Susanna Grimaudo, Michele Ciccarelli, Sofia Manara, Luca Cozzaglio, Luca Mancini, Riccardo Borroni, Armando Santoro   +9 more
doaj   +1 more source

Surgical Outcomes Following Neoadjuvant-Targeted Therapy for Advanced Differentiated Thyroid Cancer-Real-World Data. [PDF]

Clin Endocrinol (Oxf)
ABSTRACT Background Differentiated thyroid carcinoma (DTC) is typically managed surgically with favourable outcomes. However, surgery may have dire consequences when the tumour invades critical structures. Neoadjuvant therapy with tyrosine kinase inhibitors (TKIs) has emerged as a potential strategy to improve resectability and reduce morbidity in ...
Dorman A, Shendler G, Warshavsky A, Muhanna N, Horowitz G, Furman LK, Shilo S, Joshua BZ, Alon E, Remer E, Avior G, Khafif A, Gutfeld O, Izkhakov E, Mansour J, Finkel I.   +15 more
europepmc   +2 more sources

Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. [PDF]

, 2017
Recent genomic analyses have revealed substantial tumor heterogeneity across various cancers. However, it remains unclear whether and how genomic heterogeneity is constrained during tumor evolution.
Bivona, Trever G, Cai, Mei-Chun, Chen, Hong-Zhuan, Chen, Minjiang, Fu, Yujie, Gao, Wei-Qiang, Gu, Zhenyu, Jing, Ying, Ma, Pengfei, Shen, Ying, Wang, Mengzhao, Wu, Jie, Yan, Ying, Zhang, Shengzhe, Zhao, Xiaojing, Zhu, Liang, Zhuang, Guanglei   +16 more
core   +2 more sources

Dabrafenib and its potential for the treatment of metastatic melanoma

Drug Design, Development and Therapy, 2012
Alexander M Menzies,1 Georgina V Long,1,2 Rajmohan Murali3,41Melanoma Institute Australia, Sydney, New South Wales, Australia; 2Westmead Institute for Cancer Research and Crown Princess Mary Cancer Centre Westmead, Sydney, New South Wales, Australia ...
Menzies AM, Long GV, Murali R
doaj  

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. [PDF]

, 2019
BackgroundThis pooled analysis investigated the prognostic value of depth of response in two cohorts of patients with BRAFV600-mutated metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib.MethodsThe data were pooled from BRIM-2 ...
Ascierto, Paolo A, Dréno, Brigitte, Flaherty, Keith T, Hauschild, Axel, Larkin, James, Lewis, Karl D, McArthur, Grant A, McKenna, Edward, Mun, Yong, Ribas, Antoni, Wongchenko, Matthew, Yan, Yibing, Zhu, Qian   +12 more
core   +2 more sources

Impact of non‐genetic heterogeneity of BRAF‐mutant colon cancer organoids on growth kinetics, drug sensitivity and Wnt dynamics

International Journal of Cancer, EarlyView.
What's New? Patient‐derived organoids (PDOs) model tumor biology and drug response while preserving key tumor features, yet the impact of non‐genetic culture variables is poorly understood. This study examined the influence of organoid size, seeding density, and morphology on growth, drug sensitivity, and Wnt signaling in a colorectal cancer organoid ...
Viktoria Zieger, Ellen Woehr, Jasmin Traichel, Tilman Brummer, Roland Zengerle, Sabrina Kartmann, Stefan Zimmermann   +6 more
wiley   +1 more source

Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy [PDF]

, 2016
Purpose: Conjunctival melanoma (CM) is a rare but lethal form of cancer. Similar to cutaneous melanoma, CM frequently carries activating mutations in BRAF and NRAS. We studied whether CM as well as conjunctival benign and premalignant melanocytic lesions
Burg, S.H. (Sjoerd) van der, Cao, J. (Jinfeng), de Lange, M.J. (Mark J.), Dogrusöz, M. (Mehmet), Heijkants, R.C. (Renier C.), Jager, M.J. (Martine), Jochemsen, A.G. (Aart), Velden, P.A. (Pieter) van der, Verdijk, R.M. (Robert)   +8 more
core   +3 more sources

Immunotherapy‐Related Cutaneous Toxicities in Melanoma: A Dermoscopic Perspective

JEADV Clinical Practice, EarlyView.
Dermoscopy serves as a valuable tool in the everyday dermatological and oncological practice for melanoma patients, allowing for the prompt identification of immune‐related cutaneous toxicities and guiding clinicians toward appropriate therapeutic decisions.
Grażyna Kamińska‐Winciorek, Iris Zalaudek, Karolina Zarańska, Bożena Cybulska‐Stopa   +3 more
wiley   +1 more source